Zobrazeno 1 - 6
of 6
pro vyhledávání: ''
Publikováno v:
JAMA Oncol
Importance In immune checkpoint inhibitor (ICI) trials, long tails and crossovers in survival curves—which violate the proportional hazards (PH) assumption—are commonly observed, making cure or restricted mean survival time models preferable for
Autor:
Zoe B. Ciantra, Shana Criscitiello, Jason I. Kass, Jochen H. Lorch, Roy B. Tishler, Kai W. Wucherpfennig, Glenn J. Hanna, Nicole G. Chau, Adrienne M. Luoma, Ravindra Uppaluri, Danielle N. Margalit, Heather A. Jacene, Donald J. Annino, Anupam M. Desai, Bhupendra Rawal, Brendan Ross, Robert I. Haddad, Vickie Y. Jo, Jason L. Weirather, Ana Lako, Yu-Hui Chen, P.S. Catalano, Jonathan D. Schoenfeld, Hina Shah, Laura A. Goguen, Scott J. Rodig
Publikováno v:
JAMA Oncology. 6:1563
Importance Novel approaches are needed to improve outcomes in patients with squamous cell carcinoma of the oral cavity. Neoadjuvant immunotherapy given prior to surgery and combining programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte
Autor:
Martin Sökler, Ulrich Keller, Carsten Kobe, Bastian von Tresckow, Andreas Rosenwald, Stephan Mathas, Paul J Bröckelmann, Michael Fuchs, Jasmin Mettler, Julia Meissner, Peter Borchmann, Andrea Kerkhoff, Andreas Zimmermann, Stephanie Sasse, Wolfram Klapper, Helen Goergen, Rainer Ordemann, Andreas Engert, Matthias Bormann, Teresa V Halbsguth, Christian Baues, Andreas Hüttmann
Publikováno v:
JAMA Oncol
Importance In early-stage unfavorable classic Hodgkin lymphoma (cHL), conventional therapy induces high cure rates but also relevant acute and long-term toxic effects. Nivolumab is well tolerated and highly effective in relapsed/refractory cHL but ha
Autor:
Don S. Dizon, Weixiu Luo, Ursula A. Matulonis, Sarah J. Hill, Panagiotis A. Konstantinopoulos, Jennifer Curtis, Neil S. Horowitz, Christina I. Herold, Joyce F. Liu, Richard T. Penson, Stephen A. Cannistra, Cesar M. Castro, Kathryn P. Gray
Publikováno v:
JAMA Oncol
Importance To date, single-agent programmed cell death 1 protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint blockade has shown limited activity in recurrent epithelial ovarian cancer. Combination strategies of PD-1/PD-L1 inhibition
Autor:
Chul Kim, Michael R. Cook
Publikováno v:
JAMA Oncology. 5:1049
Importance Patients with HIV infection are at increased risk for cancer. Cancer is the leading cause of death among non–AIDS-defining illnesses in these patients. Immune checkpoint inhibitor (ICI) therapy has transformed the treatment of cancer. Ho
Autor:
Rajeshwari Sridhara, Meredith Libeg, Patricia Keegan, Richard Pazdur, Paul G. Kluetz, Shenghui Tang, Dickran Kazandjian, Gideon M. Blumenthal, Lijun Zhang, Sean Khozin
Publikováno v:
JAMA Oncology. 2:118
Metastatic squamous non-small-cell lung cancer (SQ NSCLC) is a serious and life-threatening malignant condition with unmet medical need. In late December 2014, the US Food and Drug Administration (FDA) obtained the data monitoring committee report of